Pharmaceutical operations remain central to large-cap healthcare discussions Balance sheet positioning frames institutional comparisons Broader sentiment reflects themes seen in s&p 500 chart Pfizer ...

Pfizer reported a quarterly loss Tuesday following a large write-down, denting shares as it confirmed 2026 financial targets with lower revenues.

Pfizer delivered a significant earnings surprise in its third-quarter results, demonstrating the pharmaceutical giant’s resilience amid a challenging year for its stock performance. The company’s ...

Pfizer is one of the largest pharmaceutical companies on the planet. It has a proven track record of finding, developing, and commercializing new drugs. The recent price advance is worth paying ...

Pfizer’s revenue soared to record heights a few years ago thanks to its coronavirus products, but growth has since slowed. The company is counting on new products, and a focus on oncology, to drive ...

Pfizer's third-quarter sales fell 6% year over year to $16.65 billion, beating the consensus of $16.59 billion. The revenue reflected an operational decline of 7%. The operational decrease was ...

Pfizer has agreed to acquire Metsera, a clinical-stage biopharmaceutical company. The transaction, announced Sept. 22, is valued at $47.50 per Metsera share in cash upon closing, for an initial ...

Pfizer Ventures announced its investment in Vibrant Therapeutics, a clinical-stage biotechnology company. The $61 million financing round included new investor Apricot Capital, with participation from ...